Etcembly Ltd reposted this
At Etcembly, we’re revolutionizing TCR engineering to meet the urgent need for effective and scalable immunotherapies. Our AI platform EMLy™ can take TCR sequences and predict stable, affinity-matured variants with optimal yield. 💡 The challenge? Therapeutic TCRs must go beyond high affinity—they also require optimal stability, expression, and developability to succeed as viable medicines. ✨ How we solve it: EMLy combines advanced Large Language Models (LLMs) with sequence- and structure-based engineering to produce TCRs with: ✔️ 5-million-fold binding affinity improvement ✔️ 5X increase in yield ✔️ 4℃ increase in thermal stability With EMLy you can supercharge the stability and developability of your asset. To find out more, visit https://lnkd.in/es4MdpfB
